



**PROLOR BIOTECH SELECTED TO PRESENT AT THE
2010 BIO INTERNATIONAL CONVENTION**

Nes-Ziona, Israel – April 30, 2010 – PROLOR Biotech, Inc. (NYSE Amex: PBTH), a company developing next generation biobetter therapeutic proteins, today announced that the company has been chosen by the BIO Selection Committee to give a corporate presentation at the 2010 BIO International Convention, to be held at McCormick Place Chicago, IL. Chief Executive Officer Avri Havron will give an overview and update of PROLOR's recent progress on Wednesday, May 5, 2010 at 9:15 am CDT.

For more information on the conference, visit <http://convention.bio.org/default.aspx>

ABOUT PROLOR BIOTECH

PROLOR Biotech, Inc. is a biopharmaceutical company applying unique technologies, including its patented CTP technology, primarily to develop longer-acting, biobetter, proprietary versions of already approved therapeutic proteins that currently generate billions of dollars in annual global sales. The CTP technology is applicable to virtually all proteins and PROLOR is currently developing long-acting versions of human growth hormone, which is in clinical development, and interferon beta, factor VII, factor IX and erythropoietin, which are in preclinical development, as well as GLP-1 and other therapeutic peptides. For more information on PROLOR, visit www.prolor-biotech.com.

PROLOR CONTACT:
Shai Novik, President
PROLOR Biotech, Inc.
Tel: +1 866 644-7811

Email: shai@prolor-biotech.com

MEDIA CONTACT:
Barbara Lindheim
GendeLLindheim BioCom Partners
+1 212 918-4650